Physician profile
Dipti S Vyas
NPI 1871508507
$1,572.64
in general payments reported to CMS, 2019-2025
32 companies · $245 in 2025
The $245 reported for 2025 was more than what 79% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $48.42 · 2021: $137 · 2022: $552 · 2023: $112 · 2024: $298 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $654.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $349.78 | 2020-2025 | Evenity, Prolia |
| Pfizer INC. | $125.43 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $99.73 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $86.74 | 2022-2025 | |
| Antares Pharma, INC. | $76.74 | 2022-2023 | Tlando, Xyosted, Nocdurna |
| Axsome Therapeutics, INC. | $69.81 | 2024-2025 | Auvelity |
| Abbott Laboratories | $60.60 | 2021-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $57.61 | 2021-2024 | Nucala, Arexvy, Shingrix |
| Amarin Pharma, INC. | $55.40 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.18 | 2021-2024 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $50.52 | 2022 | |
| Biogen, INC. | $40.02 | 2021 | |
| Janssen Pharmaceuticals, INC | $36.11 | 2021-2024 | Xarelto |
| Abbvie INC. | $35.11 | 2019-2022 | |
| Ibsa Pharma INC. | $34.90 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $32.37 | 2022 | |
| Novo Nordisk INC | $32.10 | 2022 | |
| Sanofi Pasteur INC. | $32.03 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $31.78 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $23.11 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.03 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.17 | 2025 | Gvoke Hypopen |
| Exact Sciences Corporation | $17.56 | 2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $17.08 | 2024 | Voquezna |
| Nestle Healthcare Nutrition INC. | $17.03 | 2022 | |
| Merck Sharp & Dohme LLC | $16.49 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.96 | 2022 | |
| Dynavax Technologies Corporation | $15.72 | 2023 | Heplisav-B |
| Supernus Pharmaceuticals, INC. | $14.66 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.26 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.46 | 2019 | |
| Bausch Health US, LLC | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dipti Vyas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.